Biomarkers have moved from “nice-to-have” to the backbone of drug development, says Quanterix’s Jorge Marques Signes, who argues they now shape feasibility, timelines and even payer expectations before sponsors commit thousands of patients or years of spend. “Biomarkers are not supplemental anymore,” said Marques Signes, VP of Accelerator & Clinical Services at Quanterix. “They are…
Prominent cell and gene therapy vendors in 2023
In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030. The burgeoning demand in…
Akoya Biosciences hires new chief people officer
The self-proclaimed “spatial biology company” Akoya Biosciences (NSDQ:AKYA) has appointed Marilee Moy as its chief people officer. Moy has more than three decades of experience in human resources and has worked for several life science companies, including Questcor, Counsyl, Tails Biomedical, Genentech and Johnson & Johnson. Akoya, which went public last year, had raised more…